Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
NCT05113693
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes
Interventions
DRUG:
CKD-393
DRUG:
CKD-501, D759, H053
Sponsor
Chong Kun Dang Pharmaceutical